评估颈项透明层增厚胎儿的全外显子组测序检测的临床效用与策略
该回顾性研究纳入2018年1月至2019年12月因高龄、筛查阳性或超声异常行羊膜腔穿刺的孕妇,对颈项透明层≥3.5 mm且染色体微阵列分析阴性的胎儿行全外显子组测序,发现10.42%(10/96)存在与颈项透明层增厚表型相关的致病性变异,80%(8/10)出现不良结局;颈项透明层≥3 mm者染色体异常率为23.56%(143/607),染色体微阵列分析诊断率为17.63%(107/607)。
要点
- 颈项透明层≥3 mm胎儿染色体异常率为23.56%,染色体微阵列分析诊断率为17.63%。
- 颈项透明层≥3.5 mm且染色体微阵列分析阴性者全外显子组测序额外诊断率为10.42%(10/96)。
- 全外显子组测序检出致病变异者80%(8/10)出现不良结局,包括4例引产、3例发育迟缓、1例新生儿死亡。
核心结论
- 染色体微阵列分析在颈项透明层≥3 mm胎儿中检出17.63%的染色体异常。
- 颈项透明层增厚合并额外超声发现的胎儿染色体异常率显著更高(44.62% vs 19.00%,P=.00)。
- 全外显子组测序对颈项透明层≥3.5 mm胎儿的单基因病提供10.42%的额外诊断率。
- 全外显子组测序结合基于后续产前或产后表型的数据再分析,是诊断颈项透明层增厚胎儿单基因病的最佳策略。
研究设计与样本
- 回顾性研究,纳入2018年1月至2019年12月因高龄、筛查阳性或超声异常行羊膜腔穿刺的孕妇。
- 采用染色体微阵列分析诊断染色体异常,对颈项透明层≥3.5 mm胎儿序贯行全外显子组测序。
- 新生儿定期随访至48至60月龄。
主要发现
- 11774例羊膜腔穿刺中607例(5.16%)胎儿颈项透明层≥3 mm,染色体异常检出率23.56%(143/607),包括非整倍体13.18%(80/607)及染色体缺失/重复或纯合区域10.38%(63/607)。
- 排除36例意义不明变异后,染色体微阵列分析对非整倍体及致病/可能致病染色体异常的诊断率为17.63%(107/607)。
- 464例颈项透明层≥3 mm且染色体微阵列分析阴性胎儿中,240例颈项透明层≥3.5 mm,其中96例行全外显子组测序,10.42%(10/96)检出与颈项透明层增厚表型相关的致病变异。
- 致病变异涉及DDX3X、RIT1、NIPBL、ANKRD11、PIEZO2、NF1、ASXL1、CCDC22和TUBB3基因,呈X连锁或常染色体显性遗传。
- 颈项透明层≥3.5 mm且孕中期出现额外超声发现的胎儿染色体异常率显著高于无额外发现者(44.62% vs 19.00%,P=.00)。
关键数值与推荐
- 颈项透明层≥3 mm胎儿染色体异常率23.56%(143/607)。
- 染色体微阵列分析诊断率17.63%(107/607)。
- 颈项透明层≥3.5 mm且染色体微阵列分析阴性胎儿全外显子组测序诊断率10.42%(10/96)。
- 颈项透明层≥3.5 mm合并额外超声发现者染色体异常率44.62% vs 无额外发现者19.00%(P=.00)。
临床怎么用
- 对颈项透明层≥3 mm胎儿行染色体微阵列分析以检出染色体异常。
- 对颈项透明层≥3.5 mm且染色体微阵列分析阴性胎儿可行全外显子组测序检测单基因病。
- 全外显子组测序结果应结合后续产前或产后表型进行数据再分析。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The routine recommendation for detecting monogenic disease in fetuses with increased nuchal translucency remains controversial. This study aimed to evaluate the clinical significance and optimal strategy of whole-exome sequencing in fetuses with increased nuchal translucency. STUDY DESIGN: This retrospective study included pregnancies that underwent amniocentesis due to advanced maternal age, positive screening results, or abnormal ultrasound findings between January 2018 and December 2019. Chromosomal abnormalities were diagnosed using chromosome microarray analysis. Whole-exome sequencing testing was sequentially performed in fetuses with nuchal translucency≥3.5 mm. Newborns were followed up regularly until they reached 48 to 60 months of age. RESULTS: Of the 11,774 pregnancies undergoing amniocentesis, 607 fetuses (5.16%) had nuchal translucency≥3 mm. Chromosomal abnormalities were detected in 23.56% (143/607), including aneuploidy (13.18%, 80/607) and chromosome deletion or duplication or regions of homozygosity (10.38%, 63/607). The diagnostic yield of chromosome microarray analysis for aneuploidies and pathogenic or likely pathogenic chromosome abnormalities was 17.63% (107/607), after excluding 36 cases with variants of uncertain significance. Among the 464 fetuses with nuchal translucency≥3 mm and negative chromosome microarray analysis results, 240 cases had fetal nuchal translucency≥3.5 mm, of which 96 cases underwent whole-exome sequencing testing. Whole-exome sequencing identified diagnostic variants in genes associated with an increased nuchal translucency phenotype in 10.42% (10/96) of cases. These variants involved genes of DEAD-box helicase 3 X-linked (DDX3X), Ras like without CAAX 1 (RIT1), NIPBL cohesin loading factor (NIPBL), ankyrin repeat domain containing 11 (ANKRD11), piezo type mechanosensitive ion channel component 2 (PIEZO2), Neurofibromin 1 (NF1), ASXL transcriptional regulator 1 (ASXL1), coiled-coil domain-containing protein 22 (CCDC22), and tubulin, beta-3 (TUBB3), which are inherited in either an X-linked or autosomal dominant pattern. Adverse outcomes were observed in 80% (8/10) of these cases, including 4 induced abortions, 3 cases of developmental delay, and 1 neonatal death. A total of 86 fetuses (14.17%, 86/607) had additional ultrasound findings. Fetuses with nuchal translucency≥3.5 mm and additional ultrasound findings identified during the second trimester exhibited a significantly higher rate of chromosomal abnormalities compared to those without additional findings (44.62% vs 19.00%, P=.00). Among fetuses with nuchal translucency≥3 mm and negative chromosome microarray analysis or whole-exome sequencing testing results, 90.39% (395/437, after excluding 27 pregnancies lost to follow-up) were healthy during follow-up. The remaining approximately 10% (42 cases) experienced miscarriage, induced abortion, intrauterine fetal death, or developmental delay. CONCLUSION: Chromosome microarray analysis identified chromosomal abnormalities in 17.63% of fetuses with nuchal translucency≥3 mm. Fetuses with increased nuchal translucency and additional ultrasound findings exhibited a markedly higher rate of chromosomal abnormalities. Whole-exome sequencing provided an additional diagnostic yield of 10.42% for monogenic disorders in fetuses with nuchal translucency≥3.5 mm. Whole-exome sequencing testing, combined with data reanalysis based on subsequent prenatal or postnatal phenotypes, offers an optimal strategy for diagnosing monogenic diseases in fetuses with increased nuchal translucency.
引用
- Zhou F, Yang M, Zhang Z, et al. Evaluating the clinical utility and strategy of whole-exome sequencing testing for fetuses with increased nuchal translucency. Am J Obstet Gynecol. 2025. PMID: 40381797. doi:10.1016/j.ajog.2025.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。